Search

Your search keyword '"Balkan S"' showing total 184 results
Start Over Author "Balkan S"
184 results on '"Balkan S"'

2. Integrating hepatitis C treatment into multidrug-resistant TB care

Author

Kirakosyan, O., Melikyan, N., Falcao, J., Khachatryan, N., Atshemyan, H., Oganezova, I., Aznauryan, A., Yeghiazaryan, L., Sargsyants, N., Hayrapetyan, A., Balkan, S., Hewison, C., and Huerga, H.

Subjects
Original Articles
Abstract

Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We describe the implementation aspects of a new integrated model of care in Armenia and the perceptions of the healthcare staff and patients.We used qualitative methods, including a desktop review and semi-structured individual interviews with healthcare staff and with patients receiving HCV and MDR/RR-TB treatment.The new integrated model resulted in simplified management of HCV and MDR/RR-TB at public TB facilities. Training on HCV was provided for TB clinic staff. All MDR/RR-TB patients were systematically offered HCV testing and those diagnosed with HCV, offered treatment with DAAs. Treatment monitoring was performed by TB staff in coordination with a hepatologist. The staff interviewed had a positive opinion of the new model. They suggested that additional training should be provided. Most patients were fully satisfied with the care received. Some were concerned about the increased pill burden.Integrating HCV treatment into MDR/ RR-TB care was feasible and appreciated by patients and staff. This new model facilitated HCV diagnosis and treatment among people with MDR/RR-TB. Our results encourage piloting this model in other settings.Les antiviraux à action directe (DAA) sont peu prescrits aux patients atteints d’hépatite C (HCV) chronique et de TB multirésistante ou résistante à la rifampicine (MDR/RR-TB). Nous décrivons la mise en place d’un nouveau modèle de soins intégrés en Arménie, ainsi que l’opinion du personnel soignant et des patients.Nous avons utilisé des méthodes qualitatives, comprenant un examen électronique de la documentation et des entretiens individuels semi-structurés avec le personnel soignant et les patients sous traitement pour HCV et MDR/RR-TB.Le nouveau modèle intégré a permis de simplifier la prise en charge du HCV et de la MDR/RR-TB dans les centres de soins publics de la TB. Une formation sur le HCV a été dispensée au personnel des centres antituberculeux. Tous les patients atteints de MDR/RR-TB se sont vu systématiquement proposer un test de dépistage du HCV, et un traitement par DAA a été proposé à ceux dont le résultat était positif. Le suivi du traitement a été réalisé par le personnel des centres antituberculeux, conjointement à un hépatologue. Les membres du personnel interrogés avaient une opinion positive du nouveau modèle et suggéraient de dispenser d’autres formations. La plupart des patients étaient pleinement satisfaits des soins reçus, mais certains étaient inquiets au vu du nombre accru de comprimés à prendre.L’intégration du traitement du HCV aux soins de la MDR/RR-TB s’est avérée possible et a été appréciée par les patients et le personnel soignant. Ce nouveau modèle a facilité le diagnostic et le traitement du HCV chez les patients atteints de MDR/RR-TB. Ce modèle devrait être testé dans d’autres contextes.

Published
2022

3. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

Author

Tron, L, Lert, F, Spire, B, DraySpira, R, Allègre, T, Mours, P., Riou, J.M., Sordage, M., Chennebault, J. M., Fialaire, P., Rabier, V., Froidure, M., Huguet, D., Leduc, D., Pichancourt, G., Wajsbrot, A., Bourdeaux, C., Foltzer, A., Hoen, B., HustacheMathieu, L., Abgrall, S., Barruet, R., Bouchaud, O., Chabrol, A., Mattioni, S, Mechai, F., Jeantils, V., Bernard, N., Bonnet, F., Hessamfar, M., Lacoste, D., Malvy, D., Mercié, P., Morlat, P., Paccalin, F., Pertusa, M. C., Pistone, T., Receveur, M. C., Vandenhende, M. A., Dupont, C., Freire Maresca, A., Leporrier, J., Rouveix, E., Dargere, S., de la Blanchardière, ., Martin, A., Noyon, V., Verdon, R., Rogeaux, O., Beytout, J., Gourdon, F., Laurichesse, H., Meier, F., Mortier, E., Simonpoli, A. M., Cordier, F., Delacroix, I., Garrait, V., Elharrar, B., Dominguez, S., Lascaux, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Buisson, M., Piroth, L., Waldner, A., Gruat, N., Leprêtre, A., de Truchis, P., Le Du, D, Melchior, J. Cl., Sehouane, R., Troisvallets, D., Blanc, M., BocconGibod, I., Bosseray, A., Brion, J. P., Durand, F., Leclercq, P., Marion, F., Pavese, P., BrottierMancini, E., Faba, L., RoncatoSaberan, M., BollengierStragier, O., Esnault, J. L., LeautezNainville, S., Perré, P., Froguel, E., Nguessan, M., Simon, P., Colardelle, P., Doll, J., GodinCollet, C., RoussinBretagne, S., Delfraissy, J. F., Duracinsky, M., Goujard, C., Peretti, D., Quertainmont, Y., Marionneau, J., Aissi, E., Van Grunderbeeck, N, Denes, E., DucroixRoubertou, S., Genet, C., Weinbreck, P., AugustinNormand, C., Boibieux, A., Cotte, L., Ferry, T., Koffi, J., Miailhes, P., Perpoint, T., Peyramond, D., Schlienger, I., Brunel, J. M., Carbonnel, E., Chiarello, P., Livrozet, J. M., Makhloufi, D., Dhiver, C., Husson, H., Madrid, A., Ravaux, I., de Severac, M.L., Thierry Mieg, M., Tomei, C., Hakoun, S., Moreau, J., Mokhtari, S., Soavi, M. J., Faucher, O., Ménard, A., Orticoni, M., PoizotMartin, I., Soavi, M. J., Atoui, N., Baillat, V., Faucherre, V., Favier, C., Jacquet, J. M., Le Moing, V, Makinson, A., Mansouri, R., Merle, C., Elforzli, N., Allavena, C., Aubry, O., Besnier, M., Billaud, E., Bonnet, B., Bouchez, S., Boutoille, D., Brunet, C., Feuillebois, N., Lefebvre, M., MorineauLe Houssine, P, Mounoury, O., Point, P., Raffi, F., Reliquet, V., Talarmin, J. P., Ceppi, C., Cua, E., Dellamonica, P., De SalvadorGuillouet, Durant, J., Ferrando, S., MondainMiton, V., Perbost, I., Pillet, S., ProuvostKeller, B., Pradier, C., Pugliese, P., Roger, P. M., Rosenthal, E., Sanderson, F., Hocqueloux, L., Niang, M., Prazuck, T., Arsac, P., BarraultAnstett, M.F., Ahouanto, M., Bouvet, E., Castanedo, G., CharloisOu, C., Dia Kotuba, A., EidAntoun, Z., Jestin, C., Jidar, K., Joly, V., KhuongJosses, M. A., Landgraf, N., Landman, R., Lariven, S., Leprêtre, A., Lʼhériteau, F., Machado, M., Matheron, S., Michard, F., Morau, G., Pahlavan, G., Phung, B. C., Prévot, M. H., Rioux, C., Yéni, P., BaniSadr, F., Calboreanu, A., Chakvetadze, E., Salmon, D., Silbermann, B., Batisse, D., Beumont, M., Buisson, M., Castiel, P., Derouineau, J., Eliaszewicz, M., Gonzalez, G., Jayle, D., Karmochkine, M., Kousignian, P., Pavie, J., Pierre, I., Weiss, L., Badsi, E., Bendenoun, M., Cervoni, J., Diemer, M., Durel, A., Rami, A., Sellier, P., AitMohand, H., Amirat, N., Bonmarchand, M., Bourdillon, F., Breton, G., Caby, F., Grivois, J. P., Katlama, C., Kirstetter, M., Paris, L., Pichon, F., Roudière, L., Schneider, L., Samba, M. C., Seang, S., Simon, A., Stitou, H., Tubiana, R., Valantin, M. A., Bollens, D., Bottero, J., Bui, E., Campa, P., Fonquernie, L., Fournier, S., Girard, P. M., Goetschel, A., Guyon, H. F., Lacombe, K., Lallemand, F., Lefebvre, B., Maynard, J. L., Meyohas, M. C., Ouazene, Z., Pacanowski, J., Picard, O., Raguin, G., Roussard, P., Tourneur, M., Tredup, J., Valin, N., Balkan, S., Clavel, F., Colin de Verdière, N, De Castro, N., de Lastours, V., Ferret, S., Gallien, S., Garrait, V., Gérard, L., Goguel, J., Lafaurie, M., LascouxCombe, C., Molina, J. M., Oksenhendler, E., Pavie, J., Pintado, C., Ponscarme, D., Rozenbaum, W., Scemla, A., Bonnard, P., Lassel, L., Lebrette, M. G., Lyavanc, T., Mariot, P., Missonnier, R., Ohayon, M., Pialoux, G., Treilhou, M. P., Vincensini, J. P., Gilquin, J., Hadacek, B., NaitIghil, L., Nguyen, T. H., Pintado, C., Sobel, A., Viard, J. P., Zak Dit Zbar, O., Aumaître, H., Eden, A., Ferreyra, M., Lopez, F., Medus, M., Neuville, S., Saada, M., Blum, L., Perfezou, P., Arvieux, C., Chapplain, J. M., Revest, M., Souala, F., Tattevin, P., Bord, S., BorsaLebas, F., Caron, F., Chapuzet, C., Debab, Y., Gueit, I., Etienne, M., Fartoukh, C., Feltgen, K., Joly, C., RobadayVoisin, S., Suel, P., Khuong, M. A., Krausse, J., Poupard, M., Tran Van, G., Cazorla, C., Daoud, F., Fascia, P., Frésard, A., Guglielminotti, C., Lucht, F., BernardHenry, C., Cheneau, C., Lang, J. M., de Mautort, E., Partisani, M., Priester, M., Rey, D., Majerholc, C., Zucman, D., Assi, A., Lafeuillade, A., de Jaureguiberry, J. P., Gisserot, O., Aquilina, C., Prevoteau du Clary, F., Alvarez, M., Chauveau, M., Cuzin, L., Delobel, P., Garipuy, D., Labau, E., Marchou, B., Massip, P., Mularczyk, M., Obadia, M., Ajana, F., Allienne, C., Baclet, V., de la Tribonnière, X, Huleux, T., Melliez, H., Meybeck, A., Riff, B., Valette, M., Viget, N., Bastides, F., Bernard, L., Gras, G., Guadagnin, P., May, T., Rabaud, C., Dos Santos, A, P oinsignon, Y., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Bantsima, J., CarauxPaz, P., and Patey, O.

Published
2017
Full Text
View/download PDF

4. Integrating hepatitis C treatment into multidrug-resistant TB care

Author

Kirakosyan, O., primary, Melikyan, N., additional, Falcao, J., additional, Khachatryan, N., additional, Atshemyan, H., additional, Oganezova, I., additional, Aznauryan, A., additional, Yeghiazaryan, L., additional, Sargsyants, N., additional, Hayrapetyan, A., additional, Balkan, S., additional, Hewison, C., additional, and Huerga, H., additional

Published
2022
Full Text
View/download PDF

8. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

Author

Chéret, Antoine, Bacchus-Souffan, Charline, Avettand-Fenoël, Veronique, Mélard, Adeline, Nembot, Georges, Blanc, Catherine, Samri, Assia, Sáez-Cirión, Asier, Hocqueloux, Laurent, Lascoux-Combe, Caroline, Allavena, Clotilde, Goujard, Cécile, Valantin, Marc Antoine, Leplatois, Anne, Meyer, Laurence, Rouzioux, Christine, Autran, Brigitte, Hoen, B., Bourdeaux, C., Delfraissy, J. F., Goujard, C., Amri, I., Fourn, E., Quertainmont, Y., Môle, M., Rami, A., Durel, A., Diemer, M., Parrinello, M., Allègre, T., Lafeuillade, A., Hittinger, G., Lambry, V., Carrerre, M., Philip, G., Duvivier, C., Consigny, P. H., Charlier, C., Shoai, M., Touam, F., Pialoux, G., Slama, L., LʼYavanc, T., Mathurin, P., Adda, A., Berrebi, V., Salmon, D., Chakvetadze, E., Tassadit, T., Ousseima, E., Pietri, M. P., Levy, Y., Lascaux, A. S., Lelievre, J. D., Giovanna, M., Dominguez, S., Dumont, C., Katlama, C., Valentin, M. A., Seang, S., Schneider, L., Kiorza, N., Chermak, A., Ben Abdallah, S., Simon, A., Pichon, F., Pauchard, M., Molina, J. M., Lascoux, C., Ponscarme, D., Colin De Verdiere, N., Scemla, A., De Castro, N., Rachline, A., Garrait, V., Rozenbaum, W., Ferret, S., Balkan, S., Clavel, F., Tourdjman, M., Lafaurie, M., Aslan, A., Goguel, J., Thierry, S. M., De Lastours, V., Gallien, S., Pavie, J., Delgado, J., Mededji, C., Veron, R., Abel, S., Pierre-François, S., Baringhton, C., Chennebault, J. M., Vandamme, Y. M., Fialaire, P., Rehaiem, S., Rabier, V., Abgueguen, P., Morlat, P., Vandenhende, M. A., Bernard, N., Lacoste, D., Michaux, C., Paccalin, F., Receveur, M. C., Caldato, S., Delaune, J., Ragnaud, J. M., Neau, D., Lacaze-Buzy, L., Livrozet, J. M., Jeanblanc, F., Makhloufi, D., Brunel Dalmas, F., Jourdain, J. J., Chiarello, P., Yeni, P., Phung, B., Rioux, C., Godard, C., Louni, F., El Alami Talbi, N., Catalano, G., Guiroy, F., Reynes, J., Jacquet, J. M., Fauchere, V., Merle, C., Lemoine, V., Loriette, M., Morquin, D., Makinson, A., Atoui, N., Tramoni, C., Raffi, F., Allavena, C., Bonnet, B., Bouchez, S., Feuillebois, N., Brunet-François, C., Reliquet, V., Mounoury, O., Morineau-Le-Houssine, P., Billaud, E., Brosseau, D., Hüe, H., Dellamonica, P., Vassallo, M., Leplatois, A., Durant, J., Naqvi, A., Joulié, A., Souala, F., Michelet, C., Arvieux, C., Tattevin, P., Leroy, H., Revest, M., Fily, F., Chapplain, J. M., Ratajczak, C. M., Gras, G., Bernard, L., Dailloux, J. F., Laplantine, V., Cuzin, L., Marchou, B., Larrigue, S., Chauveau, M., Balsarin, F., Obadia, M., Chéret, A., Bonne, S., Huleux, T., Ajana, F., Alcaraz, I., Baclet, V., Melliez, H., Viget, N., De La Tribonniere, X., Aissi, E., Poissy, J., Ravaux, I., Vallon, A., Varan, M., May, T., Letranchant, L., Burty, C., Briaud, A., Wassoumbou, S., Stenzel, M., Bouillon, M. P., Debab, Y., Caron, F., Gueit, I., Chapuzet, C., Borsa Lebas, F., Etienne, M., Miailhes, P., Perpoint, T., Senechal, A., Schlienger, I., Cotte, L., Augustin Normand, C., Boibieux, A., Ferry, T., Corsini, N., Braun, E., Lippran, J., Biron, F., Chidiac, C., Pailhes, S., Lipman, J., Braun, E., Koffi, J., Thoirain, V., Brochier, C., Greder Belan, A., Therby, A., Monnier, S., Ruquet, M., Garrait, V., Richier, L., Prevoteau Du Clary, F., Philibert, P., Chapus, C., Cabié, A., and Abel, S.

Published
2015
Full Text
View/download PDF

9. Cost and cost‐effectiveness of a simplified treatment model with direct‐acting antivirals for chronic hepatitis C in Cambodia

Author

Walker, J.G., Mafirakureva, N., Iwamoto, M., Campbell, L., Kim, C.S., Hastings, R.A., Doussett, J., Le Paih, M., Balkan, S., Marquardt, T., Maman, D., Loarec, A., Coast, J., and Vickerman, P.

Subjects
health care economics and organizations
Abstract

Background & Aims\ud \ud In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct‐acting antiviral (DAA) treatment. This study analysed the cost‐effectiveness of this intervention.\ud \ud \ud Methods\ud \ud Costs, quality adjusted life years (QALYs) and cost‐effectiveness of the intervention were projected with a Markov model over a lifetime horizon, discounted at 3%/year. Patient‐level resource‐use and outcome data, treatment costs, costs of HCV‐related healthcare and EQ‐5D‐5L health states were collected from an observational cohort study evaluating the effectiveness of DAA treatment under full and simplified models of care compared to no treatment; other model parameters were derived from literature. Incremental cost‐effectiveness ratios (cost/QALY gained) were compared to an opportunity cost‐based willingness‐to‐pay threshold for Cambodia ($248/QALY).\ud \ud \ud Results\ud \ud The total cost of testing and treatment per patient for the full model of care was $925(IQR $668‐1631), reducing to $376(IQR $344‐422) for the simplified model of care. EQ‐5D‐5L values varied by fibrosis stage: decompensated cirrhosis had the lowest value, values increased during and following treatment. The simplified model of care was cost saving compared to no treatment, while the full model of care, although cost‐effective compared to no treatment ($187/QALY), cost an additional $14 485/QALY compared to the simplified model, above the willingness‐to‐pay threshold for Cambodia. This result is robust to variation in parameters.\ud \ud \ud Conclusions\ud \ud The simplified model of care was cost saving compared to no treatment, emphasizing the importance of simplifying pathways of care for improving access to HCV treatment in low‐resource settings.

Published
2020

11. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV : an international cohort collaboration [plus Supplementary appendix]

Author

The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, Collins, I.J., Wools-Kaloustian, K., Goodall, R., Smith, C., Abrams, E.J., Ben-Farhat, J., Balkan, S., Davies, M.A., Edmonds, A., Leroy, V., Nuwagaba-Biribonwoha, H., Patel, K., Paul, M.E., Pinto, J., Conejo, P.R., Sohn, A., Van Dyke, R., Vreeman, R., Maxwell, N., Timmerman, V., Duff, C., Judd, A., Seage, G., Williams, P., Gibb, D.M., Bekker, L.G., Mofenson, L., Vicari, M., Essajee, S., Mohapi, E.Q., Kazembe, P.N., Hlatshwayo, M., Lumumba, M., Kekitiinwa-Rukyalekere, A., Wanless, S., Matshaba, M.S., Goetghebuer, T., Thorne, C., Warszawski, J., Galli, L., Geelen, S., Giaquinto, C., Marczynska, M., Marques, L., Prata, F., Ene, L., Okhonskaia, L., Noguera-Julian, A., Naver, L., Rudin, C., and Jourdain, Gonzague

Abstract

Background : Estimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV are necessary to inform the need for paediatric second-line formulations. We aimed to quantify the cumulative incidence of switching to second-line ART among children in an international cohort collaboration. Methods : In this international cohort collaboration study, we pooled individual patient-level data for children younger than 18 years who initiated ART (two or more nucleoside reverse-transcriptase inhibitors [NRTI] plus a non-NRTI [NNRTI] or boosted protease inhibitor) between 1993 and 2015 from 12 observational cohort networks in the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Patients who were reported to be horizontally infected with HIV and those who were enrolled in trials of treatment monitoring, switching, or interruption strategies were excluded. Switch to second-line ART was defined as change of one or more NRTI plus either change in drug class (NNRTI to protease inhibitor or vice versa) or protease inhibitor change, change from single to dual protease inhibitor, or addition of a new drug class. We used cumulative incidence curves to assess time to switching, and multivariable proportional hazards models to explore patient-level and cohort-level factors associated with switching, with death and loss to follow-up as competing risks. Findings : At the data cutoff of Sept 16, 2015, 182 747 children with HIV were included in the CIPHER dataset, of whom 93 351 were eligible, with 83 984 (90.0%) from sub-Saharan Africa. At ART initiation, the median patient age was 3.9 years (IQR 1.6-6.9) and 82 885 (88.8%) patients initiated NNRTI-based and 10 466 (11.2%) initiated protease inhibitor-based regimens. Median duration of follow-up after ART initiation was 26 months (IQR 9-52). 3883 (4.2%) patients switched to second-line ART after a median of 35 months (IQR 20-57) of ART. The cumulative incidence of switching at 3 years was 3.1% (95% CI 3.0-3.2), but this estimate varied widely depending on the cohort monitoring strategy, from 6.8% (6.5-7.2) in settings with routine monitoring of CD4 (CD4% or CD4 count) and viral load to 0.8% (0.6-1.0) in settings with clinical only monitoring. In multivariable analyses, patient-level factors associated with an increased likelihood of switching were male sex, older age at ART initiation, and initial NNRTI-based regimen (p

Published
2019

16. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

Author

Pressiat, Claire, Hirt, Déborah, Treluyer, Jean-Marc, Zheng, Yi, Morlat, Philippe, Naqvi, Alice, Tran, Laurent, Viard, Jean-Paul, Avettand-Fenoel, Véronique, Rouzioux, Christine, Meyer, Laurence, Cheret, Antoine, Hoen, B, Bourdeaux, C, Delfraissy, J, Goujard, C, Amri, I, Fourn, E, Quertainmont, Y, Môle, M, Rami, A, Durel, A, Diemer, M, Parrinello, M, Allègre, T, Lafeuillade, A, Hittinger, G, Lambry, V, Carrerre, M, Philip, G, Duvivier, C, Consigny, P, Charlier, C, Shoai, M, Touam, F, Pialoux, G, Slama, L, l'Yavanc, T, Mathurin, P, Adda, A, Berrebi, V, Salmon, D, Chakvetadze, E, Tassadit, T, Ousseima, E, Pietri, M, Levy, Y, Lascaux, A, Lelievre, J, Giovanna, M, Dominguez, S, Dumont, C, Katlama, C, Valentin, M, Seang, S, Schneider, L, Kiorza, N, Chermak, A, Ben Abdallah, S, Simon, A, Pichon, F, Pauchard, M, Molina, J, Lascoux, C, Ponscarme, D, Colin de Verdiere, N, Scemla, A, de Castro, N, Rachline, A, Garrait, V, Rozenbaum, W, Ferret, S, Balkan, S, Clavel, F, Tourdjman, M, Lafaurie, M, Aslan, A, Goguel, J, Thierry, S, de Lastours, V, Gallien, S, Pavie, J, Delgado, J, Mededji, C, Veron, R, Abel, S, Pierre-François, S, Baringhton, C, Chennebault, J, Vandamme, Y, Fialaire, P, Rehaiem, S, Rabier, V, Abgueguen, P, Vandenhende, M, Bernard, N, Lacoste, D, Michaux, C, Paccalin, F, Receveur, M, Caldato, S, Delaune, J, Ragnaud, J, Neau, D, Lacaze-Buzy, L, Livrozet, J, Jeanblanc, F, Makhloufi, D, Brunel Dalmas, F, Jourdain, J, Chiarello, P, Yeni, P, Phung, B, Rioux, C, Godard, C, Louni, F, El Alami Talbi, N, Catalano, G, Guiroy, F, Reynes, J, Jacquet, J, Fauchere, V, Merle, C, Lemoine, V, Loriette, M, Morquin, D, Makinson, A, Atoui, N, Tramoni, C, Raffi, F, Allavena, C, Bonnet, B, Bouchez, S, Feuillebois, N, Brunet-François, C, Reliquet, V, Mounoury, O, Morineau-Le-Houssine, P, Billaud, E, Brosseau, D, Hüe, H, Dellamonica, P, Vassallo, M, Leplatois, A, Durant, J, Joulié, A, Souala, F, Michelet, C, Arvieux, C, Tattevin, P, Leroy, H, Revest, M, Fily, F, Chapplain, J, Ratajczak, C, Gras, G, Bernard, L, Dailloux, J, Laplantine, V, Cuzin, L, Marchou, B, Larrigue, S, Chauveau, M, Balsarin, F, Obadia, M, Bonne, S, Huleux, T, Ajana, F, Alcaraz, I, Baclet, V, Melliez, H, Viget, N, de la Tribonniere, X, Aissi, E, Poissy, J, Ravaux, I, Vallon, A, Varan, M, May, T, Letranchant, L, Burty, C, Briaud, A, Wassoumbou, S, Stenzel, M, Bouillon, M, Debab, Y, Caron, F, Gueit, I, Chapuzet, C, Borsa Lebas, F, Etienne, M, Miailhes, P, Perpoint, T, Senechal, A, Schlienger, I, Cotte, L, Augustin Normand, C, Boibieux, A, Ferry, T, Corsini, N, Braun, E, Lippran, J, Biron, F, Chidiac, C, Pailhes, S, Lipman, J, Koffi, J, Thoirain, V, Brochier, C, Greder Belan, A, Therby, A, Monnier, S, Ruquet, M, Richier, L, Prevoteau Du Clary, F, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique (EA_7323), Université Paris Descartes - Paris 5 (UPD5), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Service de Maladies Infectieuses [CHU Nice], Hôpital l'Archet - CHU de Nice, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and CHU Pontchaillou [Rennes]

Subjects
Male, 0301 basic medicine, MESH: Raltegravir Potassium, [SDV]Life Sciences [q-bio], HIV Infections, Pharmacology, Maraviroc, MESH: HIV-1, Plasma, chemistry.chemical_compound, Pharmacology (medical), MESH: Anti-HIV Agents, MESH: Maraviroc, Darunavir, MESH: Darunavir, education.field_of_study, MESH: Middle Aged, MESH: HIV Infections, Middle Aged, Viral Load, Infectious Diseases, MESH: Young Adult, Female, MESH: Viral Load, Viral load, medicine.drug, Adult, Microbiology (medical), Anti-HIV Agents, 030106 microbiology, Population, Emtricitabine, Young Adult, 03 medical and health sciences, Pharmacokinetics, Raltegravir Potassium, medicine, Humans, education, MESH: Plasma, Models, Statistical, Ritonavir, MESH: Humans, business.industry, MESH: Adult, Raltegravir, MESH: Male, 030104 developmental biology, chemistry, HIV-1, MESH: Ritonavir, business, MESH: Female, MESH: Models, Statistical
Abstract

International audience; BackgroundThe OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, tenofovir disoproxil fumarate and emtricitabine. From month 6 to 18, the percentage of viral load values

Published
2018
Full Text
View/download PDF

20. The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis

Author

Slogrove, A.L. (Amy L.), Schomaker, M. (Michael), Davies, M.-A. (Mary-Ann), Williams, P. (Paige), Balkan, S. (Suna), Ben-Farhat, J. (Jihane), Calles, N. (Nancy), Chokephaibulkit, K. (Kulkanya), Duff, C. (Charlotte), Eboua, T.F. (Tanoh François), Kekitiinwa-Rukyalekere, A. (Adeodata), Maxwell, N. (Nicola), Pinto, J. (Jorge), Seage, G. (George), Teasdale, C.A. (Chloe A.), Wanless, S. (Sebastian), Warszawski, J. (Josiane), Wools-Kaloustian, K. (Kara), Yotebieng, M. (Marcel), Timmerman, V. (Venessa), Collins, I.J. (Intira J.), Goodall, R. (Ruth), Smith, C. (Colette), Patel, K. (Kunjal), Paul, M. (Mary), Gibb, D.M., Vreeman, R. (Rachel), Abrams, E.J. (Elaine J.), Hazra, R. (Rohan), Van Dyke, R. (Russell), Bekker, L.-G. (Linda-Gail), Mofenson, L. (Lynne), Vicari, M. (Marissa), Essajee, S. (Shaffiq), Penazzato, M. (Martina), Anabwani, G. (Gabriel), Q. Mohapi, E. (Edith), N. Kazembe, P. (Peter), Hlatshwayo, M. (Makhosazana), Lumumba, M. (Mwita), Goetghebuer, T. (Tessa), Thorne, C. (Claire), Galli, L. (Luisa), van Rossum, A. (Annemarie), Giaquinto, C. (Carlo), Marczynska, M. (Magdalena), Marques, L.C. (Laura), Prata, F. (Filipa), Ene, L. (Luminita), Okhonskaia, L. (Liubov), Rojo, P. (Pablo), Fortuny, C. (Claudia), Nave´r, L., Rudin, C. (Christoph), Le Coeur, S. (Sophie), Volokha, A. (Alla), Rouzier, V. (Vanessa), Succi, R. (Regina), Sohn, A. (Annette), Kariminia, A. (Azar), Edmonds, A. (Andrew), Lelo, P. (Patricia), Ayaya, S. (Samuel), Ongwen, P. (Patricia), Jefferys, L.F. (Laura F.), Phiri, S. (Sam), Mubiana-Mbewe, M. (Mwangelwa), Sawry, S. (Shobna), Renner, L. (Lorna), Sylla, M. (Mariam), Abzug, M.J. (Mark J.), Levin, M. (Myron), Oleske, J. (James), Chernoff, M. (Miriam), Traite, S. (Shirley), Purswani, M. (Murli), Chadwick, E.G. (Ellen G.), Judd, A. (Ali), Leroy, V. (Valériane), Slogrove, A.L. (Amy L.), Schomaker, M. (Michael), Davies, M.-A. (Mary-Ann), Williams, P. (Paige), Balkan, S. (Suna), Ben-Farhat, J. (Jihane), Calles, N. (Nancy), Chokephaibulkit, K. (Kulkanya), Duff, C. (Charlotte), Eboua, T.F. (Tanoh François), Kekitiinwa-Rukyalekere, A. (Adeodata), Maxwell, N. (Nicola), Pinto, J. (Jorge), Seage, G. (George), Teasdale, C.A. (Chloe A.), Wanless, S. (Sebastian), Warszawski, J. (Josiane), Wools-Kaloustian, K. (Kara), Yotebieng, M. (Marcel), Timmerman, V. (Venessa), Collins, I.J. (Intira J.), Goodall, R. (Ruth), Smith, C. (Colette), Patel, K. (Kunjal), Paul, M. (Mary), Gibb, D.M., Vreeman, R. (Rachel), Abrams, E.J. (Elaine J.), Hazra, R. (Rohan), Van Dyke, R. (Russell), Bekker, L.-G. (Linda-Gail), Mofenson, L. (Lynne), Vicari, M. (Marissa), Essajee, S. (Shaffiq), Penazzato, M. (Martina), Anabwani, G. (Gabriel), Q. Mohapi, E. (Edith), N. Kazembe, P. (Peter), Hlatshwayo, M. (Makhosazana), Lumumba, M. (Mwita), Goetghebuer, T. (Tessa), Thorne, C. (Claire), Galli, L. (Luisa), van Rossum, A. (Annemarie), Giaquinto, C. (Carlo), Marczynska, M. (Magdalena), Marques, L.C. (Laura), Prata, F. (Filipa), Ene, L. (Luminita), Okhonskaia, L. (Liubov), Rojo, P. (Pablo), Fortuny, C. (Claudia), Nave´r, L., Rudin, C. (Christoph), Le Coeur, S. (Sophie), Volokha, A. (Alla), Rouzier, V. (Vanessa), Succi, R. (Regina), Sohn, A. (Annette), Kariminia, A. (Azar), Edmonds, A. (Andrew), Lelo, P. (Patricia), Ayaya, S. (Samuel), Ongwen, P. (Patricia), Jefferys, L.F. (Laura F.), Phiri, S. (Sam), Mubiana-Mbewe, M. (Mwangelwa), Sawry, S. (Shobna), Renner, L. (Lorna), Sylla, M. (Mariam), Abzug, M.J. (Mark J.), Levin, M. (Myron), Oleske, J. (James), Chernoff, M. (Miriam), Traite, S. (Shirley), Purswani, M. (Murli), Chadwick, E.G. (Ellen G.), Judd, A. (Ali), and Leroy, V. (Valériane)

Abstract

Background: Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in “real-life” settings across multiple regions. We describe the geographic and temporal characteristics and mortality outcomes of APHs across multiple regions, including South America and the Caribbean, North America, Europe, sub-Saharan Africa, and South and Southeast Asia. Methods and findings: Through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), individual retrospective longitudinal data from 12 cohort networks were pooled. All children infected with HIV who entered care before age 10 years, were not known to have horizontally acquired HIV, and were followed up beyond age 10 years were included in this analysis conducted from May 2016 to January 2017. Our primary analysis describes patient and treatment characteristics of APHs at key time points, including first HIV-associated clinic visit, antiretroviral therapy (ART) start, age 10 years, and last visit, and compares these characteristics by geographic region, country income group (CIG), and birth period. Our secondary analysis describes mortality, transfer out, and lost to follow-up (LTFU) as outcomes at age 15 years, using competing risk analysis. Among the 38,187 APHs included, 51% were female, 79% were from sub-Saharan Africa and 65% lived in low-income countries. APHs from 51 countries were included (Europe: 14 countries and 3,054 APHs; North America: 1 country and 1,032 APHs; South America and the Caribbean: 4 countries and 903 APHs; South and Southeast Asia: 7 countries and 2,902 APHs; sub-Saharan Africa, 25 countries and 30,296 APHs). Observation started as early as 1982 in Europe and 1996 in sub-Saharan Africa, and continued until at least 2014 in all regions. The median (interquartile range [IQR]

Published
2018
Full Text
View/download PDF

21. The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis

Author

Slogrove, AL, Schomaker, M, Davies, MA, Williams, P, Balkan, S, Ben-Farhat, J, Calles, N, Chokephaibulkit, K, Duff, C, Eboua, TF, Kekitiinwa-Rukyalekere, A, Maxwell, N, Pinto, J, Seage, G, Teasdale, CA, Wanless, S, Warszawski, J, Wools-Kaloustian, K, Yotebieng, M, Timmerman, V, Collins, IJ, Goodall, R, Smith, C, Patel, KN, Paul, M, Gibb, D, Vreeman, R, Abrams, EJ, Hazra, R, Van Dyke, R, Bekker, LG, Mofenson, L, Vicari, M, Essajee, S, Penazzato, M, Anabwani, G, Mohapi, EQ, Kazembe, PN, Hlatshwayo, M, Lumumba, M, Goetghebuer, T, Thorne, C, Galli, L, van Rossum, Annemarie, Giaquinto, C, Marczynska, M, Marques, L (Lemelinda), Prata, F, Ene, L, Okhonskaia, L, Rojo, P, Fortuny, C, Naver, L, Rudin, C, Le Coeur, S, Volokha, A, Rouzier, V, Succi, R, Sohn, A, Kariminia, A, Edmonds, A, Lelo, P, Ayaya, S, Ongwen, P, Jefferys, LF, Phiri, S, Mubiana-Mbewe, M, Sawry, S, Renner, L, Sylla, M, Abzug, MJ, Levin, M, Oleske, J, Chernoff, M, Traite, S, Purswani, M, Chadwick, EG, Judd, A, Leroy, V, Slogrove, AL, Schomaker, M, Davies, MA, Williams, P, Balkan, S, Ben-Farhat, J, Calles, N, Chokephaibulkit, K, Duff, C, Eboua, TF, Kekitiinwa-Rukyalekere, A, Maxwell, N, Pinto, J, Seage, G, Teasdale, CA, Wanless, S, Warszawski, J, Wools-Kaloustian, K, Yotebieng, M, Timmerman, V, Collins, IJ, Goodall, R, Smith, C, Patel, KN, Paul, M, Gibb, D, Vreeman, R, Abrams, EJ, Hazra, R, Van Dyke, R, Bekker, LG, Mofenson, L, Vicari, M, Essajee, S, Penazzato, M, Anabwani, G, Mohapi, EQ, Kazembe, PN, Hlatshwayo, M, Lumumba, M, Goetghebuer, T, Thorne, C, Galli, L, van Rossum, Annemarie, Giaquinto, C, Marczynska, M, Marques, L (Lemelinda), Prata, F, Ene, L, Okhonskaia, L, Rojo, P, Fortuny, C, Naver, L, Rudin, C, Le Coeur, S, Volokha, A, Rouzier, V, Succi, R, Sohn, A, Kariminia, A, Edmonds, A, Lelo, P, Ayaya, S, Ongwen, P, Jefferys, LF, Phiri, S, Mubiana-Mbewe, M, Sawry, S, Renner, L, Sylla, M, Abzug, MJ, Levin, M, Oleske, J, Chernoff, M, Traite, S, Purswani, M, Chadwick, EG, Judd, A, and Leroy, V

Published
2018

22. Mortality and clinical outcomes in children treated with antiretroviral therapy in four African vertical programs during the first decade of paediatric HIV care, 2001-2010

Author

Ben-Farhat, J, Schramm, B, Nicolay, N, Wanjala, S, Szumilin, E, Balkan, S, and Pujades Rodriguez, M

Abstract

Objective: To assess mortality and clinical outcomes in children treated with antiretroviral therapy (ART) in four African vertical programmes between 2001 and 2010. Methods: Cohort analysis of data from HIV-infected children (

Published
2017

24. Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia

Author

Iwamoto, M., primary, Calzia, A., additional, Yann, S., additional, Pin, S., additional, Lastrucci, C., additional, Kimchamroeun, S., additional, Dimanche, C., additional, Dousset, J.-P., additional, Paih, M.L., additional, Dublineau, A., additional, Balkan, S., additional, Marquardt, T., additional, Nouhin, J., additional, Rouet, F., additional, Loarec, A., additional, and Maman, D., additional

Published
2018
Full Text
View/download PDF

26. Recovery from a large primary pontine hemorrhage

Author

ÖNAL, Z., ÖZKAYNAK, S., BALKAN, S., and KAYA, A.

Subjects
Medicine, Computerized tomography,Primary pontine hemorrhage,Recovery, Tıp
Abstract

Recovery from a large primary pontine hemorrhage is a very unusual condition. A 46-year-old man developed a sudden cerebrovascular attack resulting in tetraplegia. He had a large centrally located primary pontine hemorrhage with dimensions of 35,1 mm X 19.5 mm that was revealed by computerized tomography. He recovered almost totally. We always have to be aware of the level of consciousness while evaluating the prognosis of a primary pontine hemorrhage. By means of this case we propose a new insight for the prognostic evaluation of primary pontine hemorrhage.

Published
2016

29. Primary prevention of stroke: Guidelines of Turkish society of cerebrovascular diseases - 2015 [Inmede birincil koruma: Türk beyin damar hastaliklari dernegi inme tani VE tedavi kilavuzu - 2015]

Author

Uzuner N., Balkan S., GüNngÖr L., Dora B., Öztürk V., Isikay C.T., Nazliel B., and Selçuk Üniversitesi

Subjects
Stroke, Primary prevention, Diabetes, Hypertension, Guideline, Atrial fibrillation
Abstract

In this guideline, the brief information about primary prevention of stroke by the recent developments will be presented. Recommendation regarding the risk factors including hypertension, diabetes, dyslipidemia, smoking and alcohol usage, physical activity, dietary habits, obesity, atrial fibrillation, patent foramen ovale, asymptomatic carotid artery occlusions, sickle-cell anaemia, anticoagulant and antiagreggant usage will be offered.

Published
2015

30. Secondary prevention: Guidelines of Turkish Society of cerebrovascular diseases 2015 [Ikincil koruma: türk beyin damar hastaliklari dernegi inme tani ve tedavi kilavuzu 2015]

Author

Kutluk K., Balkan S., Coskun Ö., Melek I., Güngör L., Dora B., Öztürk V., and Selçuk Üniversitesi

Subjects
Stroke, Secondary prevention, Diabetes, Hypertension, cardiovascular diseases, Atrial fibrillation
Abstract

In this section, the brief information about secondary prevention of stroke by the recent developments will be presented. Recommendation regarding the secondary risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, symptomatic carotid occlusions, arterial dissections and patent foramen ovale and their treatment approaches will be offered.

Published
2015

31. Clinical course and outcomes of complicated mild traumatic brain injury in children: A single-center series of 124 cases

Author

Sahin Hanalioglu, Damla Hanalioglu, Cagri Elbir, Omer Selcuk Sahin, Balkan Sahin, Mehmet Erhan Turkoglu, and Huseyin Hayri Kertmen

Subjects
clinically important traumatic brain injury, computed tomography, imaging abnormality, intracranial hemorrhage, mild traumatic brain injury, neurosurgery, Neurology. Diseases of the nervous system, RC346-429
Abstract

Objective: Mild traumatic brain injury (mTBI) constitutes majority of TBI cases. A considerable portion of mTBI cases has intracranial imaging abnormalities (complicated mTBI), which pose challenges in the diagnosis and management to clinicians. Here, we aimed to evaluate the early clinical course and outcomes of pediatric complicated mTBI cases treated at a large-volume tertiary referral center. Materials and Methods: A single-center retrospective cohort study was conducted at a large-volume tertiary trauma referral center for 12-month period between 2017 and 2018. Pediatric mTBI cases with at least one of the following computed tomography (CT) findings were included a depressed skull fracture, pneumocephalus, intracranial hemorrhage, edema, or contusion. Demographic, clinical, and radiological data were collected and analyzed. Results: One hundred and twenty-four patients with complicated mTBI were identified. Falls were the leading mechanisms of trauma (71.8%). Most patients (90.3%) had a Glasgow coma score (GCS) of 15 at initial evaluation. Most frequent radiological findings on initial CT scan were epidural hematoma (EDH) (34.7%) and pneumocephalus (31.5%), followed by subdural hematoma (SDH) (19.4%), subarachnoid hemorrhage (16.9%), contusion (14.5%), and depressed skull fracture (8.1%). Radiological findings in the routine repeat CT scan were stable in 55.6% of the patients, whereas the findings progressed in 15.3% and improved in 29% of patients during this interval period (median 7 h). Neurosurgical operation was performed in 7 (5.6%) patients. Thirty-six (29%) patients were identified as having clinically important TBI (ciTBI). Average length of stay at emergency department was 9.7 ± 4.9 h, and the average length of hospital stay was 3.6 ± 2.3 days. Multivariate analysis revealed that age, GCS, pneumocephalus, depressed skull fracture, EDH, and SDH were independent predictors of ciTBI. Conclusion: Pediatric complicated mTBI is associated with higher rates of hospitalization and therefore ciTBI but relatively lower rates of need for neurosurgery. Effective decision-making tools and algorithms are needed to guide optimal management strategies of these patients.

Published
2022
Full Text
View/download PDF

33. Analytical and numerical computation of the no-load magnetic field in induction motors

Author

Kemal Leblebiciogˇlu, Anil Çekiç, Serdar Hamarat, Murat Pirgaip, Balkan S ims ir, and Bülent H. Ertan

Subjects
Engineering, business.industry, Applied Mathematics, Control engineering, Computer Science Applications, Quantitative Biology::Subcellular Processes, Variable (computer science), Constrained optimization problem, Computational Theory and Mathematics, Three-phase, Control theory, Range (aeronautics), Electrical and Electronic Engineering, business, Induction motor
Abstract

An approach to optimize the design of three‐phase induction motors for a wide speed range drive is considered. Two operating points in the speed range are taken into consideration. The problem is handled as a constrained optimization problem. An accurate model for the motor in terms of its dimensions has been developed which predicts the motor performance based on about 60 parameters of motor geometry.

Published
1998
Full Text
View/download PDF

36. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

Author

Bousser, M, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, H, Rothwell, P, Julian, D, Fieschi, G, Fieschi, C, Boysen, G, Pocock, S, Conard, J, Orgogozo, J, Inzitari, D, Erkinjuntti, T, Pasquier, F, O'Brien, J, Mas, J, Gueret, P, Lenzi, G, Leys, D, Lopez Sendon, J, Norrving, B, Ferro, J, Thygesen, K, Cowpply, B, P, Ameriso, S, Donnan, D, Lang, W, Thijs, V, Fernandes, J, Stamenova, P, Teal, P, Lavados, P, Lu, C, Poljakovic, Z, Kalita, Z, Kaste, M, Moulin, T, Vemmos, K, Diener, H, Wong, L, Nagy, Z, Chopra, J, Mccormack, P, Gensini, G, Budrys, V, Droste, D, Tan, K, Benomar, A, Cantu Brito, C, Barber, A, Koudstaal, P, Thomassen, L, Czlonkowska, A, Cunha, L, Bajenaru, O, Yakhno, N, Chen, C, Lisy, L, Zvan, B, Bryer, A, Kim, J, Vivancos, J, Wahlgren, N, Liu, S, Poungvarin, N, Hentati, F, Bahar, S, Mischenko, T, Lees, K, Abdel Masih, M, Barboza, A, Cirio, J, Crespo, E, Escaray, G, Esnaola, M, Rojas Estol, C, Ferrari, J, Fraiman, H, Garrote, M, Gatto, E, Giannaula, R, Gori, H, Herrera, G, Ioli, P, Losano, J, Povedano Reich, E, Rey, R, Rotta Escalante, R, Saredo, G, Zurru, M, Anderson, C, Bladin, C, Crimmins, D, Davis, S, Donnan, G, Dunbabin, D, Frayne, J, Gates, P, Hankey, G, Helme, R, Herkes, G, Karrasch, J, Kimber, T, Jannes, J, Landau, P, Levi, C, Lueck, C, Markus, R, Phan, T, Schwartz, R, Schultz, D, Blacker, D, Read, S, Williams, M, Aichner, F, Auff, E, Bancher, C, Binder, H, Brainin, M, Brucke, T, Eggers, C, Fertl, E, Ladurner, G, Lalouschek, W, Mamoli, B, Mitrovic, N, Noisternig, G, Schmidt, R, Vosko, M, Willeit, J, Zaruba, E, Boon, P, Bourgeois, P, Caekebeke, J, Cals, N, Cras, P, Desfontaines, P, De Deyn, P, Dieudonne, L, De Klippel, N, Laloux, P, Maertens de Noordhout, A, Merlevede, K, Michotte, A, Pandolfo, M, Peeters, A, Peeters, D, Tack, P, Van Buggenhout, E, Van Landegem, W, Vanhooren, G, Vermylen, P, Annes, M, Brondani, R, De Carvalho, J, Cendes, F, Fabio, S, Ferraz, A, De Freitas, G, Gagliardi, R, Gomes Neto, A, Haussen, S, Kowacs, P, Martins, S, Minelli, C, Moro, C, Noujaim, J, Rocha, M, Da Silva, M, Silveira, J, Yamamoto, F, Zetola, V, Baldaranov, D, Deleva, N, Haralanov, L, Milanov, I, Mintchev, D, Petrova, N, Shotekov, P, Stamenov, B, Zahariev, Z, Arts, R, Bayer, N, Beaudry, M, Berger, L, Bozek, C, Collier, T, Cote, R, Desai, H, Durocher, A, Hachinski, V, Hill, M, Hoppe, B, Howse, D, Mackey, A, Maharaj, M, Minuk, J, Moddel, G, Novak, D, Penn, A, Rabinovitch, H, Selchen, D, Shuaib, A, Silva, J, Silver, F, Spence, D, Stotts, G, Tamayo, A, Teitelbaum, J, Veloso, F, Voll, C, Winder, T, Barrientos Uribe, N, Galdames Poblete, D, Garcia Figueroa, P, Gasic Yaconi, K, Jaramillo Munoz, A, Lavados Germain, P, Lavados Montes, M, Nancupil Bello, C, Prina Pacheco, L, Vargas Canas, A, Venegas, F, Chen, P, H, Cheng, Y, Cui, L, Di, Q, Dong, Q, Fan, D, Feng, H, Huang, Y, Li, J, Li, W, Li, Z, Lin, H, Liu, M, Miao, L, Ren, H, Wang, Y, Wu, J, Zhang, W, Zhao, G, Zhao, H, Zhou, H, Antoncic, I, Demarin, V, Lusic, I, Pavlicek, I, Soldo Butkovic, S, Bar, M, Bauer, J, Kalina, M, Kanovsky, P, Jura, R, Neumann, J, Rektor, I, Skoda, O, Vaclavik, D, Eerola, A, Hillbom, M, Kinnunen, E, Koivisto, K, Numminen, H, Rissanen, A, Roine, R, Sivenius, J, Alamowitch, S, Autret, A, Avendano, S, Bataillard, M, Berthier, E, Besson, G, Bille Turc, F, Boulliat, J, Boulesteix, J, Brosset, C, Cesaro, P, Albucher, J, Clavelou, P, Colamarino, R, Crassard, I, de Broucker, T, de Bray, J, Desbordes, P, Diot, E, Ducrocq, X, Ellie, E, Faucheux, J, Giroud, M, Godefroy, O, Guillon, B, Huttin, H, Just, A, Lamy, C, Lejeune, P, Lucas, C, Macian Montoro, F, Mackowiak, A, Maillet Vioud, M, Pico, F, Milandre, L, Milhaud, D, Malbec, M, Neau, J, Pinel, J, Robin, C, Rodier, G, Rosolacci, T, Rouanet, F, Rouhart, F, Sablot, D, Servan, J, Smadja, D, Trouillas, P, Valance, J, Viader, F, Viallet, F, Wolff, V, Zagnoli, F, Zuber, M, Angerer, M, Becker, U, Berlit, P, Berrouschot, J, Biniek, R, Bitsch, A, Brodhun, R, Dichgans, M, Druschky, K, Dux, R, Faiss, J, Ferbert, A, Gahn, G, Grotemeyer, K, Goertler, M, Grau, A, Griewing, B, Grond, M, Haan, J, Haberl, R, Hamann, G, Hamer, H, Harms, L, Heide, W, Henningsen, H, Hetzel, A, Hoffmann, F, Huber, R, Isenmann, S, Jander, S, Joerg, J, Kaps, M, Kastrup, A, Kessler, C, Koehler, W, Koelmel, H, Lichy, C, Luckner, K, Malessa, R, Mallmann, A, Meyding Lamade, U, Molitor, H, Mueller Jensen, A, Muellges, W, Noth, J, Nueckel, M, Ochs, G, Poppert, H, Roether, J, Rosenkranz, M, Sander, D, Schaebitz, W, Schlachetzki, F, Schlegel, U, Schmid, E, Schneider, D, Schwarz, M, Seidel, G, Sieble, M, Sliwka, U, Stingele, R, Stoegbauer, F, Szabo, K, Topper, R, Treib, J, Weissenborn, K, Widder, B, Witte, O, Karageorgiou, K, Mitsikostas, D, Papadimitriou, A, Papathanasopoulos, P, Chan, H, Ng, P, Tsoi, T, Bartos, L, Csanyi, A, Csiba, L, Csornai, M, Dioszeghy, P, Fazekas, A, Harcos, P, Horvath, S, Kaposzta, Z, Kerenyi, L, Kincses, J, Koves, A, Nikl, J, Panczel, G, Pongracz, E, Sebestyen, K, Semjen, J, Szabo, M, Szegedi, N, Valikovics, A, Varszegi, R, Vecsei, L, Borah, N, Ichaporia, N, Kaul, S, Meenakshi Sundaram, S, Mehndiratta, M, Misra, U, Murthy, J, Nayak, D, Poncha, F, Shah, A, Singh, G, Srinivasa, R, Venkateswarlu, K, Wadia, R, Collins, R, Harbison, J, Hickey, P, Kelly, P, Murphy, S, Adami, A, Agnelli, G, Agostoni, E, Anzola, G, Arnaboldi, M, Bassi, P, Billo, G, Bottacchi, E, Bovi, P, Cappa, S, Cappelletti, C, Carolei, A, Cavallini, A, Chiodo Grandi, F, Comi, G, Consoli, D, Corsi, F, Costanzo, E, De Falco, F, Devetag, F, Di Lazzaro, V, Di Piero, V, Diomedi, M, Fattorello Salimbeni, C, Federico, F, Feleppa, M, Ferrarese, C, Gandolfo, C, Giaccaglini, E, Giaquinto, S, Giobbe, D, Giometto, B, Greco, G, Guidetti, D, Guidotti, M, Iudice, A, Lembo, G, Marengo, C, Marini, P, Melis, M, Micieli, G, Musolino, R, Mutani, R, Neri, G, Parati, E, Pastore, L, Porazzi, D, Prati, P, Procaccianti, G, Rasura, M, Rossini, P, Santilli, I, Semplicini, A, Silvestrini, M, Tanganelli, P, Tedeschi, G, Tezzon, F, Tola, M, Villani, A, Zanferrari, C, Zarcone, D, Bickuviene, I, Gumbrevicius, G, Obelieniene, D, Skaringa, A, Virketiene, I, Tharakan, J, Aleman Pedroza, J, Escamilla Garza, J, Fernandez Vera, J, Leal Cantu, R, Leon Flores, L, Lopez Ruiz, M, Reyes Gutierrez, G, Reyes Morales, S, Rivera Castano, L, Rodrigues Leyva, I, Ruiz Sandoval, J, Vega Boada, F, Belahsen, F, Kissani, N, Mosseddaq, R, Slassi, I, Yahyaoui, M, Boiten, J, Bornebroek, M, De Kort, P, De Leeuw, H, Donders, R, Franke, C, Hertzberger, L, Jansen, B, Kappelle, L, Keizer, K, Kuster, J, Limburg, M, Mulleners, W, Pop, P, Van Den Berg, J, Van Gemert, H, Verbiest, H, Weinstein, H, Clark, M, Fink, J, Gommans, J, Jayathissa, S, Kilfoyle, D, Kumar, A, Hurtig, U, Indredavik, B, Kloster, R, Salvesen, R, Drozdowski, W, Fryze, W, Klimek, A, Kochanowski, J, Kozubski, W, Ksiazkiewicz, B, Kwiecinski, H, Kuczynska Zardzewialy, A, Motta, E, Nowacki, P, Nyka, W, Opala, G, Pierzchala, K, Pniewski, J, Podemski, R, Selmaj, K, Stelmasiak, Z, Stepien, A, Strzelecka Gorzynska, M, Szczudlik, A, Wajgt, A, Wiszniewska, M, Wlodek, A, Canhao, P, Correia, C, Grilo Goncalves, J, Machado Candido, J, Salgado, A, Bulboaca, A, Campeanu, A, Lazar, T, Marginean, I, Minea, D, Pascu, I, Pereanu, M, Perju Dumbrava, L, Popescu, C, Simu, M, Stefanache, F, Toldisan, I, Tuta, S, Zaharia, C, Alifirova, V, Arkhipov, S, Balunov, O, Balyazin, V, Belkin, A, Belova, A, Boiko, A, Bogdanov, E, Butko, D, Chukhlovina, M, Doronin, B, Ermilova, E, Evzelman, M, Fedin, A, Fedorova, N, Golikov, K, Golovkin, V, Gusev, E, Gustov, A, Jakupov, E, Kamchatnov, P, Khabirov, F, Kirienko, A, Klimov, I, Klocheva, E, Kotov, S, Kuznetsov, A, Laskov, V, Levin, Y, Mashkova, N, Nazarov, A, Novikova, L, Odinak, M, Parfenov, V, Pilipenko, P, Pokrovsky, A, Poverennova, I, Rodoman, G, Roshkovskaya, L, Shirokov, E, Shmyriov, V, Sholomov, I, Skoromets, A, Skvortsova, V, Spirin, N, Stakhovskaya, L, Sharov, M, Sherman, M, Shutov, A, Strachunskaya, E, Stulin, I, Suslina, Z, Volosevitch, A, Vorobiev, P, Vorobyeva, O, Voronkova, L, Voskresenskaya, O, Zhuliov, N, Chan, B, Chang, H, Ramani, N, Brozman, M, Dvorak, M, Dzugan, J, Garay, R, Gdovinova, Z, Gurcik, L, Krastev, G, Kukumberg, P, Kurca, E, Meluch, S, Nyeky, M, Turcani, P, Vyletelka, J, Klanjscek, G, Zujovic, E, Zupan, M, Bester, F, Carr, J, Coetzee, C, Frost, A, Gardiner, J, Giampaolo, D, Kesler, S, Lurie, D, Retief, C, Roos, J, Bae, H, Cha, J, Cho, K, Heo, J, Kim, E, Lee, B, Lee, K, Lee, J, Rha, J, Yoon, B, Alvarez Sabin, J, Arboix Damunt, A, De Arce Borda, A, Asensi Alvarez JM, Bermejo Pareja, F, Botia Paniagua, E, Casado, I, Naranjo, I, Castillo Sanchez, J, Chamorro Sanchez, A, Davalos Errando, A, Diaz Marin, C, Diez Tejedor, E, Egido Herrero JA, Fernandez Bolanos, R, Fernandez Fernandez, O, Figuerola Roig, A, Geffner Sclarsky, D, Gil Nunez, A, Gomez Sanchez JC, Gomez Escalonilla Escobar CI, Gonzalez Masegosa, A, Gonzalez Menacho, J, Gracia Fleta, F, Izquierdo Ayuso, G, Jimenez Hernandez, D, Jimenez Martinez, C, Lago Martin, A, Lainez Andres JM, Larracoechea Jausoro, J, Lopez Fernandez JC, Maestre Moreno, J, Marti Vilalta JL, Martin Gonzalez, R, Masjuan Vallejo, J, Medina Rodriguez, A, Molto Jorda JM, Moreno Carre tero MJ, Moris de le Tassa, G, Morlan Gracia, L, Mostacero Miguez, E, Osuna Pulido, T, Pareja Martinez, A, Pinedo Brochado, A, Pons Amate JM, Rodriguez Alvarez JR, Roquer Gonzalez, J, Sanahuja Montesinos, J, Sanchez Sanchez MC, Segura Martin, T, Serena Leal, J, Tejada Garcia, J, Trejo Gabriel JM, Vivancos Mora, J, Andersson, B, Bysell, S, Cederin, B, Laska, A, Lindgren, A, Petersson, T, Wallen, T, Baumgartner, R, Beer, H, Hirt, L, Hungerbuehler, H, Lyrer, P, Michel, P, Mueller, F, Tettenborn, B, Chang, K, Jeng, J, Lien, L, Lin, R, Liu, C, Po, H, Wu, S, Chankrachang, S, Laptikultham, S, Nidhinandana, S, Pongpakdee, S, Benammou, S, Frih Ayed, M, Gouider, R, Mhiri, C, M'Rabet, A, Mrissa, R, Balkan, S, Can, U, Dalkara, T, Kirbas, D, Kumral, E, Ozdemir, G, Ozeren, A, Ozmenoglu, M, Ozturk, S, Lebedynets, V, Maly, V, Moskovko, S, Orzheshkovskyy, V, Smolanka, V, Yavors'Ka, V, Zozulya, I, Bamford, J, Barber, M, Barer, D, Baron, J, Bath, P, Broughton, D, Brown, M, Chataway, J, Curless, R, Darawil, K, Datta, P, Dennis, M, Durairaj, R, Egbuji, J, Ellis, S, Ford, G, Freeman, A, Fulcher, R, Gray, C, Harrington, F, Hudson, C, Iveson, E, James, M, Jenkinson, D, Kalra, L, Kelly, D, Krishnamoorthy, S, Langhorne, P, Magorrian, M, Macleod, M, Macwalter, R, Markus, H, Muhiddin, K, Muir, K, Murphy, P, Power, M, Price, C, Rashed, K, Robinson, T, Rudd, A, Sanmuganathan, P, Sharma, J, Shaw, L, Shetty, H, Smithard, D, Tyrrell, P, Vahidassr, M, Venables, G, Watt, M, White, R, Bousser, M, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, H, Rothwell, P, Ferrarese, C, PERFORM study, I, PERFORM STUDY, Investigator, Tedeschi, Gioacchino, Cras, Patrick, De Deyn, Peter Paul, and et al.

Subjects
perform study, Male, Thromboxane, International Cooperation, Receptors, Thromboxane, antiplatelet therapy, terutroban, Cardiovascular Disease, Receptors, 80 and over, Stroke, Aged, 80 and over, Aspirin, Ischemic Attack, Transient, Ischemic Attack, Transient, Double-Blind Method, Endpoint Determination, Dose-Response Relationship, Drug, Humans, Aged, Propionates, Naphthalenes, Treatment Outcome, Platelet Aggregation Inhibitors, Cardiovascular Diseases, Middle Aged, Female, Propionic Acids, Neurology, Terutroban, Anesthesia, tp receptor antagonist, stroke, secondary prevention, aspirin, Cardiology, Platelet aggregation inhibitor, Settore MED/26 - Neurologia, stroke prevention, Drug, Cardiology and Cardiovascular Medicine, medicine.drug, Human, medicine.medical_specialty, Dose-Response Relationship, Internal medicine, medicine, Dementia, In patient, business.industry, Platelet Aggregation Inhibitor, schemic, medicine.disease, DementiaI, transient ischemic attack, Ischemic stroke, Human medicine, Neurology (clinical), business, Propionic Acid, Naphthalene
Abstract

Background: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. Methods and Results: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged ≥55 years, having suffered an ischemic stroke (≤3 months) or a transient ischemic attack (≤8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2–4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. Conclusions: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.

Published
2009
Full Text
View/download PDF

40. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?

Author

Rolland, E, Checchi, F, Pinoges, L, Balkan, S, Guthmann, J, and Guerin, P

Subjects
parasitic diseases, health care economics and organizations
Abstract

OBJECTIVE: To compare the cost-effectiveness of malaria treatment based on presumptive diagnosis with that of malaria treatment based on rapid diagnostic tests (RDTs). METHODS: We calculated direct costs (based on experience from Ethiopia and southern Sudan) and effectiveness (in terms of reduced over-treatment) of a free, decentralised treatment programme using artesunate plus amodiaquine (AS + AQ) or artemether-lumefantrine (ART-LUM) in a Plasmodium falciparum epidemic. Our main cost-effectiveness measure was the incremental cost per false positive treatment averted by RDTs. RESULTS: As malaria prevalence increases, the difference in cost between presumptive and RDT-based treatment rises. The threshold prevalence above which the RDT-based strategy becomes more expensive is 21% in the AS + AQ scenario and 55% in the ART-LUM scenario, but these thresholds increase to 58 and 70%, respectively, if the financing body tolerates an incremental cost of 1 euro per false positive averted. However, even at a high (90%) prevalence of malaria consistent with an epidemic peak, an RDT-based strategy would only cost moderately more than the presumptive strategy: +29.9% in the AS + AQ scenario and +19.4% in the ART-LUM scenario. The treatment comparison is insensitive to the age and pregnancy distribution of febrile cases, but is strongly affected by variation in non-biomedical costs. If their unit price were halved, RDTs would be more cost-effective at a malaria prevalence up to 45% in case of AS + AQ treatment and at a prevalence up to 68% in case of ART-LUM treatment. CONCLUSION: In most epidemic prevalence scenarios, RDTs would considerably reduce over-treatment for only a moderate increase in costs over presumptive diagnosis. A substantial decrease in RDT unit price would greatly increase their cost-effectiveness, and should thus be advocated. A tolerated incremental cost of 1 euro is probably justified given overall public health and financial benefits. The RDTs should be considered for malaria epidemics if logistics and human resources allow.

Published
2006

41. Development and Validation of a Novel Methodological Pipeline to Integrate Neuroimaging and Photogrammetry for Immersive 3D Cadaveric Neurosurgical Simulation

Author

Sahin Hanalioglu, Nicolas Gonzalez Romo, Giancarlo Mignucci-Jiménez, Osman Tunc, Muhammet Enes Gurses, Irakliy Abramov, Yuan Xu, Balkan Sahin, Ilkay Isikay, Ilkan Tatar, Mustafa Berker, Michael T. Lawton, and Mark C. Preul

Subjects
3D rendering, depth estimation, neuroanatomy, neuroimaging, neurosurgical training, photogrammetry, Surgery, RD1-811
Abstract

BackgroundVisualizing and comprehending 3-dimensional (3D) neuroanatomy is challenging. Cadaver dissection is limited by low availability, high cost, and the need for specialized facilities. New technologies, including 3D rendering of neuroimaging, 3D pictures, and 3D videos, are filling this gap and facilitating learning, but they also have limitations. This proof-of-concept study explored the feasibility of combining the spatial accuracy of 3D reconstructed neuroimaging data with realistic texture and fine anatomical details from 3D photogrammetry to create high-fidelity cadaveric neurosurgical simulations.MethodsFour fixed and injected cadaver heads underwent neuroimaging. To create 3D virtual models, surfaces were rendered using magnetic resonance imaging (MRI) and computed tomography (CT) scans, and segmented anatomical structures were created. A stepwise pterional craniotomy procedure was performed with synchronous neuronavigation and photogrammetry data collection. All points acquired in 3D navigational space were imported and registered in a 3D virtual model space. A novel machine learning-assisted monocular-depth estimation tool was used to create 3D reconstructions of 2-dimensional (2D) photographs. Depth maps were converted into 3D mesh geometry, which was merged with the 3D virtual model’s brain surface anatomy to test its accuracy. Quantitative measurements were used to validate the spatial accuracy of 3D reconstructions of different techniques.ResultsSuccessful multilayered 3D virtual models were created using volumetric neuroimaging data. The monocular-depth estimation technique created qualitatively accurate 3D representations of photographs. When 2 models were merged, 63% of surface maps were perfectly matched (mean [SD] deviation 0.7 ± 1.9 mm; range −7 to 7 mm). Maximal distortions were observed at the epicenter and toward the edges of the imaged surfaces. Virtual 3D models provided accurate virtual measurements (margin of error

Published
2022
Full Text
View/download PDF

42. Contralateral vs. Ipsilateral Approach to Superior Hypophyseal Artery Aneurysms: An Anatomical Study and Morphometric Analysis

Author

Balkan Sahin, Serdar Onur Aydin, Mehmet Ozgur Yilmaz, Tahsin Saygi, Sahin Hanalioglu, Goktug Akyoldas, Oguz Baran, and Talat Kiris

Subjects
superior hypophyseal artery, aneurysm, contralateral, ipsilateral, approach, microsurgical anatomy, Surgery, RD1-811
Abstract

IntroductionSurgical clipping of superior hypophyseal artery (SHA) aneurysms is a challenging task for neurosurgeons due to their close anatomical relationships. The development of endovascular techniques and the difficulty in surgery have led to a decrease in the number of surgical procedures and thus the experience of neurosurgeons in this region. In this study, we aimed to reveal the microsurgical anatomy of the ipsilateral and contralateral approaches to SHA aneurysms and define their limitations via morphometric analyses of radiological anatomy, three-dimensional (3D) modeling, and surgical illustrations.MethodFive fixed and injected cadaver heads underwent dissections. In order to make morphometric measurements, 75 cranial MRI scans were reviewed. Cranial scans were rendered with a module and used to produce 3D models of different anatomical structures. In addition, a medical illustration was drawn that shows different sizes of aneurysms and surgical clipping approaches.ResultsFor the contralateral approach, pterional craniotomy and sylvian dissection were performed. The contralateral SHA was reached from the prechiasmatic area. The dissected SHA was approached with an aneurysm clip, and maneuverability was evaluated. For the ipsilateral approach, pterional craniotomy and sylvian dissection were performed. The ipsilateral SHA was reached by mobilizing the left optic nerve with left optic nerve unroofing and left anterior clinoidectomy. MRI measurements showed that the area of the prechiasm was 90.4 ± 36.6 mm2 (prefixed: 46.9 ± 10.4 mm2, normofixed: 84.8 ± 15.7 mm2, postfixed: 137.2 ± 19.5 mm2, p

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results